Published in J Med Chem on January 31, 2012
CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos (2006) 1.24
Novel nanostructured paper with ultrahigh transparency and ultrahigh haze for solar cells. Nano Lett (2014) 1.21
Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos (2010) 1.19
Mechanistic investigation of substrate oxidation by Ce(IV) reagents in acetonitrile. J Org Chem (2003) 1.18
Solvent-dependent chemoselectivities in Ce(IV)-mediated oxidative coupling reactions. Org Lett (2003) 1.17
In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos (2003) 1.16
Mechanistic studies of Ce(IV)-mediated oxidation of beta-dicarbonyls: solvent-dependent behavior of radical cation intermediates. J Org Chem (2007) 1.14
Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys (2003) 1.11
Solvent-dependent chemoselectivities in additions of beta-carbonyl imines to allyltrimethylsilane with CTAN. J Org Chem (2004) 1.10
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol (2005) 1.08
CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos (2007) 1.07
An efficient and general approach to beta-functionalized ketones. Org Lett (2007) 1.05
Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos (2011) 1.01
Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J Am Chem Soc (2002) 1.01
The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4. Arch Biochem Biophys (2010) 0.97
Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol (2007) 0.96
Electrospun Sb/C fibers for a stable and fast sodium-ion battery anode. ACS Nano (2013) 0.95
On the nature of the oxidative heterocoupling of lithium enolates. J Am Chem Soc (2011) 0.94
Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug Chem (2014) 0.94
Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol (2007) 0.93
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens. J Med Chem (2003) 0.93
CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis. Drug Metab Dispos (2007) 0.93
Thermoresponsive assembly of charged gold nanoparticles and their reversible tuning of plasmon coupling. Angew Chem Int Ed Engl (2012) 0.92
Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity. Arch Biochem Biophys (2005) 0.92
Reduction of beta-hydroxyketones by SmI2/H2O/Et3N. Org Lett (2005) 0.92
Next-Generation Lithium Metal Anode Engineering via Atomic Layer Deposition. ACS Nano (2015) 0.91
A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos (2003) 0.91
Molecular clips that undergo heterochiral aggregation and self-sorting. Angew Chem Int Ed Engl (2002) 0.90
Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol (2008) 0.90
Chelation-controlled diastereoselective reduction of alpha-fluoroketones. J Am Chem Soc (2005) 0.90
Tin anode for sodium-ion batteries using natural wood fiber as a mechanical buffer and electrolyte reservoir. Nano Lett (2013) 0.90
Catalytic Ni(II) in reactions of SmI2: Sm(II)- or Ni(0)-based chemistry? J Am Chem Soc (2011) 0.89
Investigation of anticholinergic and non-steroidal anti-inflammatory prodrugs which reduce chemically induced skin inflammation. J Appl Toxicol (2011) 0.89
A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate. AAPS J (2014) 0.89
Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol (2003) 0.89
Mild conversion of beta-diketones and beta-ketoesters to carboxylic acids. J Org Chem (2006) 0.89
Grafting single-walled carbon nanotubes with highly hybridizable DNA sequences: potential building blocks for DNA-programmed material assembly. Angew Chem Int Ed Engl (2007) 0.89
Studies on the mechanism, selectivity, and synthetic utility of lactone reduction using SmI(2) and H(2)O. J Am Chem Soc (2009) 0.88
Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos (2006) 0.87
The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Dispos (2006) 0.87
Formation of the active species of cytochrome p450 by using iodosylbenzene: a case for spin-selective reactivity. Chemistry (2007) 0.87
Effects of interleukin 1β (IL-1β) and IL-1β/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Curr Drug Metab (2012) 0.87
Solvent-dependent diastereoselectivities in reductions of beta-hydroxyketones by SmI2. Org Lett (2004) 0.86
Mechanistic complexity in organo-SOMO activation. Angew Chem Int Ed Engl (2010) 0.86
Catalytic, atom-economical radical arylation of epoxides. Angew Chem Int Ed Engl (2012) 0.86
Peripheral site acetylcholinesterase inhibitors targeting both inflammation and cholinergic dysfunction. Bioorg Med Chem Lett (2010) 0.86
Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactions. Chem Res Toxicol (2006) 0.86
Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos (2011) 0.85
Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Arch Biochem Biophys (2004) 0.85
A noncovalent approach to antiparallel beta-sheet formation. J Am Chem Soc (2002) 0.85
Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads. Bioconjug Chem (2016) 0.85
Mechanistic study of samarium diiodide-HMPA initiated 5-exo-trig Ketyl-Olefin coupling: the role of HMPA in post-electron transfer steps. J Am Chem Soc (2008) 0.84
Absolute quantification of aldehyde oxidase protein in human liver using liquid chromatography-tandem mass spectrometry. Mol Pharm (2013) 0.84
Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Chem Res Toxicol (2004) 0.84
In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract. Drug Metab Dispos (2009) 0.84
Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos (2011) 0.84
An analysis of the regioselectivity of aromatic hydroxylation and N-oxygenation by cytochrome P450 enzymes. Drug Metab Dispos (2004) 0.84
Predicting drug-drug interactions in drug discovery: where are we now and where are we going? Curr Opin Drug Discov Devel (2005) 0.83
Uncovering the mechanism of the Ag(I)/persulfate-catalyzed cross-coupling reaction of arylboronic acids and heteroarenes. J Am Chem Soc (2013) 0.83
Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation. Drug Metab Dispos (2012) 0.82
Three-dimensional quantitative structure-activity relationship analysis of cytochromes p450: effect of incorporating higher-affinity ligands and potential new applications. Drug Metab Dispos (2005) 0.82
Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme. Drug Metab Dispos (2012) 0.82
Facile Route to Tetrasubstituted Pyrazoles Utilizing Ceric Ammonium Nitrate. Synlett (2009) 0.81
Solvent-dependent oxidative coupling of 1-aryl-1,3-dicarbonyls and styrene. Tetrahedron (2009) 0.81
Porous amorphous FePO4 nanoparticles connected by single-wall carbon nanotubes for sodium ion battery cathodes. Nano Lett (2012) 0.81
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction. Drug Metab Dispos (2011) 0.81
Back-scattering interferometry: a versatile platform for the study of free-solution versus surface-immobilized hybridization. Chem Asian J (2011) 0.81
Visual detection of sub-femtomole DNA by a gold nanoparticle seeded homogeneous reduction assay: toward a generalized sensitivity-enhancing strategy. Biosens Bioelectron (2010) 0.81
Kinetic isotope effects implicate the iron-oxene as the sole oxidant in P450-catalyzed N-dealkylation. J Am Chem Soc (2004) 0.80
Application of cytochrome P450 drug interaction screening in drug discovery. Comb Chem High Throughput Screen (2010) 0.80
Synthesis of gamma-halogenated ketones via the Ce(IV)-mediated oxidative coupling of cyclobutanols and inorganic halides. Tetrahedron Lett (2009) 0.80
Uncovering the mechanistic role of HMPA in the samarium Barbier reaction. J Am Chem Soc (2010) 0.80
Efficient protein renaturation using tunable hemifluorinated anionic surfactants as additives. Chem Commun (Camb) (2009) 0.80
In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. Drug Metab Dispos (2012) 0.79
The role of proton donors in SmI2-mediated ketone reduction: new mechanistic insights. J Am Chem Soc (2004) 0.79
Active site mutations of cytochrome p450cam alter the binding, coupling, and oxidation of the foreign substrates (R)- and (s)-2-ethylhexanol. Arch Biochem Biophys (2002) 0.79
Depolarized and fully active cathode based on Li(Ni0.5Co0.2Mn0.3)O2 embedded in carbon nanotube network for advanced batteries. Nano Lett (2014) 0.79
Solid-phase parallel synthesis of 4-beta-D-ribofuranosylpyrazolo[4,3-d]pyrimidine nucleosides. Nucleosides Nucleotides Nucleic Acids (2005) 0.79
Mechanistic study of beta-substituent effects on the mechanism of ketone reduction by SmI(2). J Am Chem Soc (2002) 0.79